Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

BACKGROUND: The morbidity and mortality of adult diseases caused by S. pneumoniae increase with age and presence of underlying chronic diseases. Currently, two vaccine technologies against S. pneumoniae are used: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugat...

Descripción completa

Detalles Bibliográficos
Autores principales: Malene B, Mikkelsen, Oyvind, Husby, Tor, Molden, David N, Mwaura, Jens, Olsen, Nanna V, Kristensen, Jeffrey, Vietri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413527/
https://www.ncbi.nlm.nih.gov/pubmed/37559118
http://dx.doi.org/10.1186/s12962-023-00458-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413527/
https://www.ncbi.nlm.nih.gov/pubmed/37559118
http://dx.doi.org/10.1186/s12962-023-00458-4

Ejemplares similares